| Variables | Overall survival | Progression-free survival | Univariate | Multivariate | Univariate | Multivariate | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value |
| AFP ≤400/>400 | 0.166 (0.046, 0.604) | 0.006 | 0.234 (0.063, 0.869) | 0.030 | 0.368 (0.163, 0.832) | 0.016 | 0.326 (0.107, 0.994) | 0.049 |
| Age (years) ≤60/>60 | 0.524 (0.178, 1.540) | 0.240 | | | 1.880 (0.847, 4.171) | 0.121 | 2.632 (0.751, 9.223) | 0.130 |
| ALT (U/L) ≤35/>35 | 0.648 (0.233, 1.807) | 0.407 | | | 0.373 (0.157, 0.890) | 0.026 | 0.390 (0.152, 1.002) | 0.051 |
| AST (U/L) ≤40/>40 | 0.658 (0.224, 1.935) | 0.447 | | | 0.804 (0.362, 1.784) | 0.591 | | |
| BCLC stage A + B/C | 1.055 (0.294, 3.788) | 0.935 | | | 0.863 (0.342, 2.174) | 0.754 | | |
| Child–Pugh stage A/B | 2.334 (0.520, 10.47) | 0.268 | | | 1.009 (0.400, 2.542) | 0.985 | | |
| DEB-TACE procedures ≤2/>2 | 1.098 (0.395, 3.046) | 0.858 | | | 0.865 (0.405, 1.849) | 0.709 | | |
| Diabetes, no/yes | 0.755 (0.169, 3.372) | 0.713 | | | 0.841 (0.286, 2.467) | 0.752 | | |
| Diameter (cm) ≤5/>5 | 0.264 (0.057, 1.228) | 0.090 | 0.561 (0.084,3.762) | 0.551 | 0.330 (0.119, 0.912) | 0.033 | 1.190 (0.277, 5.117) | 0.816 |
| Extrahepatic metastasis, no/yes | 0.825 (0.289, 2.352) | 0.825 | | | 0.477 (0.217, 1.051) | 0.066 | 0.745 (0.253, 2.194) | 0.594 |
| Hepatitis B, no/yes | 0.783 (0.275, 2.229) | 0.647 | | | 0.589 (0.253, 1.374) | 0.221 | | |
| Hypertension, no/yes | 0.581 (0.181, 1.864) | 0.362 | | | 0.623 (0.240, 1.614) | 0.33 | | |
| Immunotherapy, no/yes | 0.780 (0.266, 2.289) | 0.651 | | | 0.810 (0.352, 1.865) | 0.621 | | |
| Other treatments, no/yes | 2.257 (0.615, 8.282) | 0.220 | | | 2.481 (0.970, 6.343) | 0.058 | 2.334 (0.655, 8.319) | 0.191 |
| PLT×109/L | 1.002 (0.997, 1.007) | 0.350 | | | 1.004 (1.000, 1.008) | 0.033 | 0.999 (0.995, 1.004) | 0.796 |
| Portal vein invasion, no/yes | 0.351 (0.126, 0.980) | 0.046 | 0.283 (0.076, 1.046) | 0.058 | 0.561 (0.235, 1.337) | 0.192 | 0.772 (0.201, 2.972) | 0.707 |
| PT (s) ≤14/>14 | 1.528 (0.430, 5.427) | 0.512 | | | 2.426 (0.832, 7.071) | 0.104 | 3.951 (0.946, 16.505) | 0.060 |
| Sex, female/male | 0.177 (0.023, 1.351) | 0.095 | 0.509 (0.059, 4.399) | 0.539 | 0.566 (0.213, 1.504) | 0.253 | | |
| Targeted therapy, no/yes | 0.434 (0.122, 1.539) | 0.196 | 0.761 (0.190, 3.048) | 0.699 | 0.556 (0.242, 1.278) | 0.167 | 0.860 (0.332, 2.229) | 0.756 |
| Tumor number, single/multiple | 0.379 (0.126, 1.139) | 0.084 | 0.311 (0.073, 1.327) | 0.115 | 0.448 (0.189, 1.061) | 0.068 | 0.252 (0.064, 1.003) | 0.050 |
|
|
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; PLT, platelets; BCLC, Barcelona Clinic Liver Cancer strategy; DEB-TACE, drug-eluting transarterial chemoembolization; PLT, platelet; PT, prothrombin time.
|